NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Recommendation of "Moderate Buy" by Brokerages

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $41.30.

Several research firms have weighed in on NAMS. Stifel Nicolaus began coverage on NewAmsterdam Pharma in a report on Tuesday, June 10th. They set a "buy" rating and a $44.00 target price on the stock. Citigroup began coverage on NewAmsterdam Pharma in a report on Tuesday, June 17th. They set a "buy" rating and a $42.00 target price on the stock. Needham & Company LLC restated a "buy" rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a report on Thursday. They set a "neutral" rating and a $27.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on NewAmsterdam Pharma in a report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 target price on the stock.

Insider Transactions at NewAmsterdam Pharma

In other news, COO Douglas F. Kling sold 100,000 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $19.29, for a total transaction of $1,929,000.00. Following the completion of the transaction, the chief operating officer directly owned 44,000 shares in the company, valued at $848,760. This represents a 69.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director James N. Topper acquired 8,584 shares of NewAmsterdam Pharma stock in a transaction dated Monday, June 16th. The shares were acquired at an average price of $19.50 per share, with a total value of $167,388.00. Following the completion of the purchase, the director owned 3,022,153 shares in the company, valued at approximately $58,931,983.50. The trade was a 0.28% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 12,364 shares of company stock valued at $236,839 and have sold 198,612 shares valued at $4,025,887. Corporate insiders own 20.84% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NAMS. Avanza Fonder AB grew its position in shares of NewAmsterdam Pharma by 21.0% during the 2nd quarter. Avanza Fonder AB now owns 7,505 shares of the company's stock worth $136,000 after purchasing an additional 1,300 shares in the last quarter. Atle Fund Management AB grew its position in shares of NewAmsterdam Pharma by 45.9% during the 2nd quarter. Atle Fund Management AB now owns 157,223 shares of the company's stock worth $2,847,000 after purchasing an additional 49,440 shares in the last quarter. PTM Wealth Management LLC acquired a new position in shares of NewAmsterdam Pharma during the 2nd quarter worth approximately $256,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of NewAmsterdam Pharma by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company's stock worth $5,898,000 after purchasing an additional 34,563 shares in the last quarter. Finally, Woodline Partners LP grew its position in shares of NewAmsterdam Pharma by 0.5% during the 1st quarter. Woodline Partners LP now owns 2,442,397 shares of the company's stock worth $49,996,000 after purchasing an additional 11,615 shares in the last quarter. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Stock Up 5.1%

Shares of NAMS traded up $1.06 during mid-day trading on Monday, reaching $21.98. The company's stock had a trading volume of 599,934 shares, compared to its average volume of 741,886. The business has a fifty day moving average of $19.28 and a 200 day moving average of $20.25. The company has a market cap of $2.47 billion, a price-to-earnings ratio of -11.69 and a beta of -0.03. NewAmsterdam Pharma has a 1 year low of $14.06 and a 1 year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. The firm had revenue of $2.98 million for the quarter, compared to analysts' expectations of $1.46 million. On average, analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.